Press

Silo Wellness Announces LOI for Potentially Largest Psilocybin Retreat Center in Oregon and the World – If November’s Election Is Favorable; and an Oregon Real Estate Law and Psilocybin Industry Primer

Oct 20 • 19 min read

Silo Wellness Inc. (CSE: SILO | OTCQB: SILFF | FSE: 3K7A), Oregon’s only publicly traded psychedelics company, is pleased to announce it has executed a binding term sheet for a joint venture with New Frontier Ranch in the majestic Green Springs area of Jackson County Oregon, east of Ashland, pending the results of the opt-out ballot…

Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio

Oct 19 • 2 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that as of October 18, 2022, it has been granted patent no. 11,471,417 by the United States Patent Office. This United States patent provides protection for a therapeutic composition of a small group of deuterated N,N-dimethyltryptamine (“DMT”)…

Origin Therapeutics’ Portfolio Company, Clairvoyant, Approved for Phase 2 Psilocybin Therapy Trial; First Clinical Site Initiated in Finland

Oct 19 • 2 min read

Origin Therapeutics Holdings Inc. (CSE: ORIG), an actively managed, psychedelics industry-focused investment issuer, today announced that one of its portfolio companies, Clairvoyant Therapeutics, has received regulatory approval from the Finnish Medicines Agency (FIMEA) to proceed with the company’s Phase 2 clinical trial investigating psilocybin for the treatment of alcohol use disorder (AUD) in Finland. The clinical trial, titled CLA-PSY-201,…

atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology

Oct 18 • 3 min read

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders today announced the initiation of the Phase 1 proof-of-concept (PoC) clinical trial of intranasal INB-01, a sol-gel based, excipient (drug-delivery) technology. This is a Phase 1 two-stage, open-label, randomized study of the safety, tolerability, and effective brain…

Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics

Oct 18 • 2 min read

Silo Pharma, Inc. (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced it has entered into an agreement with Columbia University pursuant to which Silo has been granted an extension for its option to license certain assets currently under development, including Alzheimer’s disease and Stress Induced Anxiety “The first steps…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435